人表皮生长因子受体-2 阳性乳腺癌：早期、晚期和复发性疾病的当前管理。
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
机构信息
University of California at Los Angeles, Los Angeles,California, USA.
出版信息
Curr Opin Obstet Gynecol. 2011 Feb;23(1):37-43. doi: 10.1097/gco.0b013e3283414e87.
Abstract
PURPOSE OF REVIEW
This review describes the current treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer with a focus on recently reported clinical trials.Treatment of resistant disease and central nervous system metastases will be reviewed as will new agents that are being developed to target HER2-amplified breast cancers.
RECENT FINDINGS
Recent studies evaluating trastuzumab-resistant breast cancer have shown a benefit of continuing trastuzumab with chemotherapy or with another HER2-targeted agent.Targeting the vascular endothelial growth factor, mammalian target of rapamycin, and PI3 kinase pathways in addition to HER2 may enhance efficacy compared with individual agents. Several novel anti-HER2 compounds are being evaluated with promising early data.
SUMMARY
HER2-positive breast cancer has traditionally been associated with poor prognosis.However, treatment with HER2-targeted therapies has changed the natural history of this disease. Greater success depends on elucidating mechanisms of resistance and exploring new methods of blocking signal transduction via HER2 and related pathways.
摘要
目的综述
本文主要介绍了人表皮生长因子受体 2（HER2）阳性乳腺癌的治疗方法，重点关注了最近报道的临床试验。我们还将回顾耐药性疾病和中枢神经系统转移的治疗方法，以及正在开发用于治疗 HER2 扩增型乳腺癌的新药物。
最近发现
最近评估曲妥珠单抗耐药性乳腺癌的研究表明，继续使用曲妥珠单抗联合化疗或另一种 HER2 靶向药物治疗具有获益。与单一药物相比，针对血管内皮生长因子、雷帕霉素哺乳动物靶蛋白和 PI3 激酶通路联合 HER2 可能会提高疗效。目前正在评估几种新型抗 HER2 化合物，早期数据显示出良好的效果。
总结
HER2 阳性乳腺癌传统上与预后不良相关。然而，HER2 靶向治疗改变了这种疾病的自然病程。更大的成功取决于阐明耐药机制，并探索通过 HER2 及相关通路阻断信号转导的新方法。
相似文献
1
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.人表皮生长因子受体-2 阳性乳腺癌：早期、晚期和复发性疾病的当前管理。
Curr Opin Obstet Gynecol. 2011 Feb;23(1):37-43. doi: 10.1097/gco.0b013e3283414e87.
2
A systematic review of dual targeting in HER2-positive breast cancer.HER2 阳性乳腺癌的双重靶向治疗系统评价。
Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
3
[Her2 positive breast cancer: practices].[人表皮生长因子受体2阳性乳腺癌：诊疗实践]
Bull Cancer. 2011 Feb;98(2):154-63.
4
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .超越曲妥珠单抗和拉帕替尼：HER2阳性乳腺癌的新选择
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e2.
5
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.针对 HER2 靶向治疗耐药的策略演进：针对 PI3K/Akt/mTOR 通路。
Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015.
6
New HER2-positive targeting agents in clinical practice.临床实践中的新型 HER2 阳性靶向药物。
Curr Oncol Rep. 2014;16(1):359. doi: 10.1007/s11912-013-0359-8.
7
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.曲妥珠单抗和拉帕替尼治疗人表皮生长因子受体 2 阳性乳腺癌脑转移女性的系统评价。
Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5.
8
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.联合靶向 HER2 和 VEGFR2 治疗 HER2 扩增型乳腺癌脑转移。
Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27. doi: 10.1073/pnas.1216078109. Epub 2012 Oct 15.
9
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.对在拉帕替尼时代之前接受基于曲妥珠单抗治疗进展的HER2阳性晚期乳腺癌患者临床结局的回顾性评估。
Clin Breast Cancer. 2008 Oct;8(5):436-42. doi: 10.3816/CBC.2008.n.053.
10
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.一项关于阿法替尼、曲妥珠单抗和拉帕替尼用于局部晚期HER2阳性乳腺癌患者的新辅助、随机、开放标签II期试验。
Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15.
引用本文的文献
1
Radiomics early assessment of post chemotherapy cardiotoxicity in cancer patients using 2D echocardiography imaging an interpretable machine learning study.基于二维超声心动图成像的癌症患者化疗后心脏毒性的影像组学早期评估：一项可解释的机器学习研究
Sci Rep. 2025 Aug 22;15(1):30888. doi: 10.1038/s41598-025-02687-4.
2
Synthesis and Anticancer Evaluation of -Alkylated (-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition.α-烷基化（α-查尔酮衍生物的合成与抗癌评估：聚焦雌激素受体抑制作用
Int J Mol Sci. 2025 Jan 20;26(2):833. doi: 10.3390/ijms26020833.
3
Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.了解 TNFR2 信号在乳腺癌肿瘤微环境中的作用。
J Exp Clin Cancer Res. 2024 Nov 28;43(1):312. doi: 10.1186/s13046-024-03218-1.
4
Overview on Current Trends and Emerging Therapies in the Chemotherapy of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.人表皮生长因子受体2阳性乳腺癌患者化疗的当前趋势与新兴疗法概述
Galen Med J. 2023 Aug 20;12:e3021. doi: 10.31661/gmj.v12i0.3021. eCollection 2023.
5
Synthesis and Evaluation of Thiazolyl-indole-2-carboxamide Derivatives as Potent Multitarget Anticancer Agents.噻唑基吲哚-2-甲酰胺衍生物作为强效多靶点抗癌剂的合成与评价
ACS Omega. 2024 Sep 24;9(40):41944-41967. doi: 10.1021/acsomega.4c06889. eCollection 2024 Oct 8.
6
Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series.玛格妥昔单抗联合化疗为HER2阳性转移性乳腺癌患者拓展治疗选择：病例报告系列
Front Oncol. 2024 Aug 16;14:1419246. doi: 10.3389/fonc.2024.1419246. eCollection 2024.
7
A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice.协同杂交小鼠中 ERBB2 驱动的乳腺肿瘤发生和转移的易感性基因特征。
EBioMedicine. 2024 Aug;106:105260. doi: 10.1016/j.ebiom.2024.105260. Epub 2024 Jul 26.
8
Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective.肿瘤浸润淋巴细胞（TILS）与乳腺癌中的PD-L1表达：从病理学家角度对当前证据及预后意义的综述
Cancers (Basel). 2023 Sep 8;15(18):4479. doi: 10.3390/cancers15184479.
9
Therapeutic significance of molecular hybrids for breast cancer research and treatment.分子杂合体在乳腺癌研究与治疗中的治疗意义。
RSC Med Chem. 2022 Nov 29;14(2):218-238. doi: 10.1039/d2md00356b. eCollection 2023 Feb 22.
10
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.SALL4 在 HER2+ 乳腺癌进展中的作用：调节 PI3K/AKT 通路。
Int J Mol Sci. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292.
本文引用的文献
1
2
Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.曲妥珠单抗治疗T1ab期、淋巴结阴性、人表皮生长因子受体2过表达的乳腺癌
J Clin Oncol. 2010 Oct 1;28(28):e541-2. doi: 10.1200/JCO.2010.29.7952. Epub 2010 Jul 26.
3
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.三阴性乳腺癌对多西他赛和卡铂为基础的新辅助治疗的差异性反应。
Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.
4
Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.与HER2阴性乳腺癌女性相比，曲妥珠单抗改善了HER2阳性乳腺癌女性的预后。
J Clin Oncol. 2010 Jul 10;28(20):e337; author reply e338-9. doi: 10.1200/JCO.2010.28.2525. Epub 2010 May 17.
5
The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.抗糖尿病药物二甲双胍抑制曲妥珠单抗耐药的肿瘤起始乳腺癌干细胞的自我更新和增殖。
Breast Cancer Res Treat. 2011 Apr;126(2):355-64. doi: 10.1007/s10549-010-0924-x. Epub 2010 May 11.
6
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.曲妥珠单抗-DM1 的 I 期研究，一种 HER2 抗体药物偶联物，每 3 周给予 1 次，用于治疗 HER2 阳性转移性乳腺癌患者。
J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.
7
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.曲妥珠单抗新辅助治疗人表皮生长因子受体 2 阳性乳腺癌：GeparQuattro 研究结果。
J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.
8
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.曲妥珠单抗联合表柔比星和环磷酰胺一线治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者：来自曲妥珠单抗、环磷酰胺和表柔比星（HERCULES）试验的心脏安全性和疗效数据。
J Clin Oncol. 2010 Mar 20;28(9):1473-80. doi: 10.1200/JCO.2009.21.9709. Epub 2010 Feb 22.
9
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.奈拉替尼，一种不可逆的 ErbB 受体酪氨酸激酶抑制剂，用于治疗晚期 ErbB2 阳性乳腺癌患者。
J Clin Oncol. 2010 Mar 10;28(8):1301-7. doi: 10.1200/JCO.2009.25.8707. Epub 2010 Feb 8.
10
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.拉帕替尼单药或联合曲妥珠单抗治疗 ErbB2 阳性、曲妥珠单抗耐药的转移性乳腺癌的随机研究。
J Clin Oncol. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. Epub 2010 Feb 1.
Zotero 插件